Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Medscape Medical News, August 08, 2023 Study Questions Use of Branded Inhalers for COPD Researchers said their analysis found that a generic product approved in 2019 was equally effective as the ...

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects ...

Whether you are lightly exercising or are going about regular activities, COPD means you may find yourself ... as long as you breathed in. If you inhaled for 2 seconds, exhale for 4, but don ...

Current treatment options for COPD include bronchodilators such as beta2-agonists and anticholinergics, standalone or combination inhaled corticosteroids (ICS), and other combination medications.

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Digital inhalers improve adherence but have not significantly impacted patient outcomes; affordability and education are crucial. Digital technologies effectively deliver pulmonary rehabilitation ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

“We’re trying to treat conditions like asthma and COPD with these inhalers, and we’re actually making it harder to breathe,” said Jyothi Tirumalasetty, a clinical assistant professor at ...

but it also can be very helpful in COPD, so it has to be prescribed properly.” Ms Bishop asked that people who use inhalers bring them along “so we can show them how to best use them and check ...

Asthma is a serious chronic condition, and it’s best managed with the help of a doctor and medications like corticosteroid and albuterol inhalers ... the Children’s Pulmonary Institute ...